Cytek Biosciences Inc (CTKB)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.86 | 6.21 | 7.33 | 6.99 | 6.97 | 7.20 | 7.93 | 7.53 | 9.26 | 10.70 | 10.47 | 10.26 | 13.43 | 14.74 | 7.70 | 7.66 | 7.86 |
| Quick ratio | 4.11 | 4.42 | 5.29 | 4.87 | 4.67 | 4.91 | 5.58 | 5.29 | 6.96 | 8.23 | 8.26 | 8.47 | 11.34 | 12.63 | 5.68 | 6.07 | 6.23 |
| Cash ratio | 4.11 | 4.42 | 5.29 | 4.87 | 4.67 | 4.91 | 5.58 | 5.29 | 6.96 | 8.23 | 8.26 | 8.47 | 11.34 | 12.63 | 5.68 | 6.07 | 6.23 |
Based on the provided data, we analyzed the liquidity ratios of Cytek Biosciences Inc, focusing on the current ratio, quick ratio, and cash ratio.
1. Current Ratio: The current ratio measures the company's ability to cover its short-term obligations with its current assets. Cytek Biosciences Inc shows consistent strength in this area, with the ratio ranging from 5.86 to 14.74 over the period analyzed. The ratio generally stayed well above 1, indicating a healthy liquidity position.
2. Quick Ratio: The quick ratio, also known as the acid-test ratio, provides a more stringent measure of liquidity by excluding inventory from current assets. Cytek Biosciences Inc maintained a solid quick ratio throughout the period, with values ranging from 4.11 to 12.63. This suggests the company has a robust ability to meet its short-term liabilities with its most liquid assets.
3. Cash Ratio: The cash ratio is the most conservative liquidity measure, focusing solely on the ability to cover current liabilities with cash and cash equivalents. Cytek Biosciences Inc demonstrated a consistently strong cash position, with ratios ranging from 4.11 to 12.63. This indicates the company has sufficient cash on hand to meet its immediate obligations without relying on other current assets.
Overall, the liquidity ratios of Cytek Biosciences Inc indicate a healthy financial position, with strong abilities to meet short-term obligations and cover liabilities using liquid assets. The company's consistent performance in these liquidity metrics suggests sound financial management and sufficient liquidity to support its operations and growth.
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 179.31 | 188.32 | 205.26 | 223.54 | 265.83 | 315.51 | 341.97 | 394.99 | 278.71 | 303.58 | 281.80 | 257.69 | 241.13 | 225.10 | 236.72 | 231.70 | 204.27 |
The cash conversion cycle of Cytek Biosciences Inc has fluctuated over the years, indicating variations in the efficiency of its cash management. The cycle decreased from 204.27 days at December 31, 2020, to a low of 179.31 days at December 31, 2024. This trend suggests that the company has been able to shorten the time it takes to convert its resources into cash.
However, it is worth noting that there were periods where the cash conversion cycle increased significantly, such as at March 31, 2023, when it reached 394.99 days. This spike may indicate challenges in efficiently managing the company's working capital during that specific period.
Overall, monitoring the cash conversion cycle of Cytek Biosciences Inc is crucial for evaluating its liquidity and operational efficiency. A lower cash conversion cycle generally indicates a more efficient use of resources and faster inflow of cash, which can be positive for the company's financial health.